LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Miles, D.W., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C.H., Xu, B., Wardley, A.M., Kaen, D., Andrade, L., Semiglazov, V., Reinisch, M., Patre, M., Morales, L., Russell, K., DonVolume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.2243
Date:
September, 2020
File:
PDF, 117 KB
2020